Fore Biotherapeutics

Executive Summary

Fore Biotherapeutics is a private, Philadelphia-based biotechnology company focused on developing next-generation oncology therapies. Its lead program, plixorafenib, is an investigational, next-generation BRAF inhibitor designed to target a broad range of BRAF gene alterations in cancer cells, including those not addressed by earlier-generation BRAF inhibitors. The compound is currently in Phase 2 clinical development, targeting indications such as BRAF-mutated solid tumors. By addressing resistance and broader mutation coverage, plixorafenib has the potential to improve outcomes for patients who do not respond to or become resistant to existing therapies. The company operates at the intersection of precision oncology and targeted small molecule therapeutics, with a singular focus on advancing plixorafenib through clinical trials.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 data readout for plixorafenib in BRAF-mutated solid tumors40% success
• Q4 2026Regulatory meeting (e.g., End-of-Phase 2) to discuss pivotal trial design50% success
• TBDPotential partnership or licensing deal for plixorafenib30% success